Skip to main content

Press Releases View all 6 hits

Cavidi Selected to Present at Cavendish Global Health Impact Forum
EIB supports Cavidi’s development of HIV viral load monitoring device
Cavidi and Burnet Institute sign CD4 license agreement

Cavidi and Burnet Institute sign CD4 license agreement

Press Releases   •   Nov 15, 2013 09:29 GMT

Leading Swedish HIV diagnostic company Cavidi today announced the signing of a license agreement for technology in the detection of CD4 T-cell levels. The CD4 test, developed by the Burnet Institute in Melbourne, Australia, and a long time partner to Cavidi, can be added to Cavidi’s Viral Load test on the next generation automated bench top instrument.

Cavidi joins UIC Business Accelerator

Cavidi joins UIC Business Accelerator

Press Releases   •   Sep 06, 2013 10:13 GMT

Cavidi, leading Swedish HIV companion diagnostic supplier, joins Uppsala Innovation Centre (UIC), a business incubator for growth companies in the Uppsala region.

News View all 12 hits

Cavidi finalists in Uppsala Innovation Award 2018

Cavidi finalists in Uppsala Innovation Award 2018

News   •   Apr 21, 2018 13:21 GMT

Cavidi were proud to be nominated as a finalist for the Innovation Award for the Uppsala region among all companies. http://foretagargalanuppsala.se/hem/finalister2018/

Cavidi with new financial strength is getting ready to fill an important gap in the global fight against HIV
Cavidi at ASLM2016

Cavidi at ASLM2016

News   •   Dec 02, 2016 10:56 GMT

Partners in Health begin VL testing at St Marc Clinic, Haiti

Partners in Health begin VL testing at St Marc Clinic, Haiti

News   •   May 11, 2016 08:00 GMT

Partners in Health have begun to use Cavidi's ExaVir Load for Viral Load testing of HIV patients in Haiti

Blog posts 2 hits

Could RT technology help close the EID gap?

Blog posts   •   Jul 23, 2012 10:30 GMT

There are around 370,000 new infant infections worldwide each year. A significant number of these children will die if they are not diagnosed early and started on antiretroviral drugs (ARVs). The problem is not the lack of ARVs as much as a lack of proper HIV early infant diagnostics (EID). Recent reports indicate that RT-technology may be an answer to improved access to (EID).

Commentary on ”Reverse Innovation”

Commentary on ”Reverse Innovation”

Blog posts   •   Apr 19, 2012 11:04 GMT

How innovations originating from low-income countries may provide solutions that can help in developed countries.

Images View all 7 hits

HIV treatment scale-up and new WHO ARV guidelines 2013

HIV treatment scale-up an...

GENEVA - New HIV treatment guidelines by WHO recommend offering antiretroviral therapy (ART) earlier. Recent evidence indicates that earl...

License Creative Commons Attribution
Download
Size

254 KB • 893 x 600 px

Swedish Ministry of Health presents SWECARE Export Award 2012

Swedish Ministry of Healt...

STOCKHOLM - Swedish Minister for Children and the Elderly, Maria Larsson presents the Export Award to Cavidi CEO, John Reisky de Dubnic (...

License Creative Commons Attribution
Download
Size

1.17 MB • 2007 x 1527 px

SWECARE Export Award 2102

SWECARE Export Award 2102

License Creative Commons Attribution
Download
Size

197 KB • 600 x 800 px

SWECARE Export Award 2102

SWECARE Export Award 2102

The Swecare Export Award is to encourage and highlight successful Swedish companies and create good examples of successful export venture...

License Creative Commons Attribution
Download
Size

27.3 KB • 364 x 194 px

Videos 1 hit

Cavidi innovation

Cavidi innovation

Cavidi's innovation is aimed at closing the gap betweenr the market need for Viral Load and current capabilities for decentralised testin...

License Creative Commons Attribution
Download
Size

640 x 360 px

Documents 1 hit

MSF report on the development needs in HIV viral load monitoring access

Routine use of viral load testing makes business sense: it will save money on drugs with effective monitoring of patients. MSF identifies the needs of a solution in a wish list on p23. This is the market opportunity that Cavidi is seeking to address with our new platform meeting requirements that MSF have identified for laboratory-based tests. Cavidi ref on p 5,20,21,23,30,and 31.